This single arm study will assess the feasibility of use, safety and tolerability of Avastin(bevacizumab) in combination with chemoradiation therapy in patients with locally advanced unresectable non-squamous non-small cell lung cancer.An initial cohort of patients will receive Avastin 7.5mg/kg iv every 3 weeks, in combination with concurrent thoracic radiation for 6.6 weeks and chemotherapy (cisplatin 75 mg/m2 iv and vinorelbine 15mg/m2 iv administered according to a standard treatment protocol). If no dose-limiting toxicities are observed, a second cohort of patients will receive Avastin at a dose of 15mg/kg iv every 3 weeks, in combination with a similar treatment regimen to that of the first cohort. After 5 cycles of combination treatment, Avastin monotherapy will be administered for a further 4 cycles. The anticipated time on study treatment is 3-12 months, and the target sample size is <100 individuals.

Inclusion Criteria:

• patients >=18 years with locoregional advanced unresectable non-squamous NSCLC;
• ECOG performance status of 0 or 1;
• no prior thoracic head and neck irradiation or surgical resection for current lung cancer.

Exclusion Criteria:

• mixed, non-small cell and small cell tumors;
• mixed adeno-squamous carcinomas with a predominant squamous component;
• evidence of tumor invasion or encasement of major vessels;
• history of grade >=2 hemoptysis;
• presence of cavitations in lung lesions at baseline.